A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-27 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
=== Metals === Pure alkali metals are dangerously reactive with air and water and must be kept away from heat, fire, oxidising agents, acids, most organic compounds, halocarbons, plastics, and moisture. They also react with carbon dioxide and carbon tetrachloride, so that normal fire extinguishers are counterproductive when used on alkali metal fires. Some Class D dry powder extinguishers designed for metal fires are effective, depriving the fire of oxygen and cooling the alkali metal. Experiments are usually conducted using only small quantities of a few grams in a fume hood. Small quantities of lithium may be disposed of by reaction with cool water, but the heavier alkali metals should be dissolved in the less reactive isopropanol. The alkali metals must be stored under mineral oil or an inert atmosphere. The inert atmosphere used may be argon or nitrogen gas, except for lithium, which reacts with nitrogen. Rubidium and caesium must be kept away from air, even under oil, because even a small amount of air diffused into the oil may trigger formation of the dangerously explosive peroxide; for the same reason, potassium should not be stored under oil in an oxygen-containing atmosphere for longer than 6 months.
The most commonly reported experience is a "clear-headed" feeling of inebriation – a form of "lucid drunkenness". Chemist, historian, and absinthe distiller Ted Breaux has claimed that the alleged secondary effects of absinthe may be because some of the herbal compounds in the drink act as stimulants, while others act as sedatives, creating an overall lucid effect of awakening. The long-term effects of moderate absinthe consumption in humans remain unknown, although herbs traditionally used to produce absinthe are reported to have both painkilling and antiparasitic properties. Today it is known that absinthe does not cause hallucinations. It is widely accepted that reports of hallucinogenic effects resulting from absinthe consumption were attributable to the poisonous adulterants being added to cheaper versions of the drink in the 19th century, such as oil of wormwood, impure alcohol (contaminated possibly with methanol), and poisonous colouring matter – notably (among other green copper salts) cupric acetate and antimony trichloride (the last-named being used to fake the ouzo effect).
==== Placental production ==== The role of the placenta in progestogen production varies by species. In the sheep, horse, and human, the placenta takes over the majority of progestogen production, whereas in other species the corpus luteum remains the primary source of progestogens. In the sheep and human, progesterone is the major placental progestogen. The equine placenta produces a variety of progestogens, primarily 5α-dihydroprogesterone and 5α,20α-tetrahydroprogesterone, beginning on day 60. A complete luteo-placental shift occurs by day 120–150.
=== Endocrine === The drug may cause adrenal insufficiency so the level of the adrenocortical hormones should be monitored while taking it. Oral ketoconazole at a dosage range of 400 to 2,000 mg/day has been found to result in a rate of gynecomastia of 21%.
Sources: en.wikipedia.org
== Resurgence == By the late 2010s, many observers, including The New York Times, pointed to Detroit's economic and cultural resurgence. This resurgence was primarily due to private and public investment revitalizing the city's social and economic dynamics. Detroit has achieved a renewed sense of interest through reinvestment and revamped social policies. It serves as a model for other areas to learn how to re-energize their urban centers. In 2024, the United States Census Bureau reported that Detroit experienced a slight population increase in its 2023 estimates, marking the city's first recorded growth since 1957. Evidence of Detroit's resurgence is most readily found in the Midtown Area and the Central Business District, which have attracted a number of high-profile investors. Most notably, Dan Gilbert has heavily invested in the acquisition and revitalization of a number of historic buildings in the Downtown area. A primary focus of private real estate investment has been to position Detroit's Central Business District as an attractive site for the investment of technology companies such as Amazon, Google, and Microsoft. Approaches to the private investment of Midtown, however, have prioritized re-establishing Midtown as the cultural and commercial center of the city. Midtown Cultural Connection's DIA Plaza Project, for instance, aims to unify the city's cultural district—which includes the Detroit Institute of Arts, Detroit Public Library, the Charles H.
== Research == The MRL/MpJ mouse strain was selectively bred by scientists to have an autoimmune genetic disorder (retained through inbreeding) to be used as a model for autoimmune disease research. After making puncture wounds in their ears, these mice were observed to completely regenerate from these wounds without development of scar tissue. In further research, this mouse strain has been observed to have the ability to also regenerate cardiac tissue, displays a resistance to muscle dystrophy, and is resistant to experiencing hyperglycemia from a diet high in fats.
=== Neuropsychiatric disorders === Methylene blue inhibits monoamine oxidase, inhibits the glutamatergic system (via inhibition of NO synthase and soluble guanylate cyclase), modulates mitochondrial function (by acting as an electron acceptor), and decreases the activation of inflammasomes NLRP3 and NLRC4. As a result, it's been considered potentially useful in neuropsychiatric disorders. In humans it has been tried for (listed in decreasing order of evidence quality): bipolar disorder (especially depressive symptoms), Alzheimer's disease, claustrophobia, ifosfamide encephalopathy, and schizophrenia. With methylene blue, a higher dose does not necessarily work better than a lower dose.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.